发明申请
- 专利标题: Benzimidazole-derivatives as factor Xa inhibitors
- 专利标题(中): 苯并咪唑衍生物作为因子Xa抑制剂
-
申请号: US10849436申请日: 2004-05-19
-
公开(公告)号: US20050009829A1公开(公告)日: 2005-01-13
- 发明人: Marc Nazare , Michael Wagner , Volkmar Wehner , Hans Matter , Matthias Urmann , Kurt Ritter
- 申请人: Marc Nazare , Michael Wagner , Volkmar Wehner , Hans Matter , Matthias Urmann , Kurt Ritter
- 申请人地址: DE frankfurt am Main
- 专利权人: Aventis Pharma Deutschland GmbH
- 当前专利权人: Aventis Pharma Deutschland GmbH
- 当前专利权人地址: DE frankfurt am Main
- 优先权: EP03011305.4 20030519
- 主分类号: C07D235/24
- IPC分类号: C07D235/24 ; C07D401/12 ; C07D401/14 ; C07D403/12 ; C07D409/14 ; C07D413/12 ; C07D413/14 ; C07D417/14 ; C07D471/04 ; C07D473/08 ; C07D495/04 ; A61K31/52 ; A61K31/4709 ; A61K31/513 ; A61K31/517 ; C07D473/02 ; C07
摘要:
The present invention relates to compounds of the formula I, wherein R0, R1, R2, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.
公开/授权文献
- US07741341B2 Benzimidazole-derivatives as factor Xa inhibitors 公开/授权日:2010-06-22
信息查询